Fundamentals screen · refreshed after the Sep 28, 2026 close
Low P/E with growing sales: Healthcare
Profitable companies priced below 12× earnings whose revenue is still growing. Price-to-earnings uses trailing-twelve-month net income. Low multiples can signal value or a business the market expects to shrink — growing revenue helps separate the two.
| # | Company | Price | P/E | Revenue YoY | Net margin | Mkt cap |
|---|---|---|---|---|---|---|
| 1 | UHSUniversal Health ServicesHealthcare | $177.48 | 6.9× | +8.3% | 7.7% | $10.46B |
| 2 | AUPHAurinia PharmaceuticalsHealthcare | $16.52 | 7.0× | +18.9% | 45.0% | $2.20B |
| 3 | THCTenet Healthcare Corporation NewHealthcare | $257.93 | 9.3× | +6.8% | 14.7% | $20.77B |
| 4 | ACADAcadia PharmaceuticalsHealthcare | $20.53 | 9.3× | +16.4% | 10.2% | $3.54B |
| 5 | AVAHAveanna Healthcare HoldingsHealthcare | $12.69 | 10.1× | +13.7% | 6.0% | $2.77B |
| 6 | SOLVSolventumHealthcare | $89.54 | 10.6× | +2.2% | 4.2% | $15.24B |
Method & sources
Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology
Informational screen, not a recommendation.